遠大醫藥(00512.HK)引進全球創新二尖瓣置換醫療器械
格隆匯11月28日丨遠大醫藥(00512.HK)公吿，集團與Innov Heart S.r.l.達成股權投資及產品引進戰略合作協議。集團將以約4380萬歐元為代價取得Innov Heart 約17.8%的股權及用於二尖瓣置換的全球創新醫療器械 Saturn 在大中華區(中國大陸、香港、澳門、台灣)的獨家開發、生產及商業化權益。本次股權投資的交割及授權協議的履行尚需經意大利相關政府機構對於外商投資和技術引進的審閲。
Saturn為集團繼冠脈及外周血管介入藥塗球囊、神經介入取栓支架、血管及心腔診斷設備、鐳射消融平台、心衰治療系統後，在精準介入領域取得的又一全球創新產品，此次戰略合作亦是本集團在打造國際領先的心腦血管精準介入診療平台的一次重要佈局。
至此，集團已實現在該領域中六個方向創新產品的全方位佈局，順利如期完成了年初制定的發展規劃目標，成為在心腦血管精準介入診療領域中產品佈局方向最廣、疾病覆蓋最全的公司之一。
Innov Heart位於意大利，是一家專注於創新型經導管二尖瓣介入治療醫療系統開發的醫療器械公司，致力於為瓣膜疾病患者提供創新治療方式，其創始團隊在心臟瓣膜疾病領域深耕十餘年，有着十分豐富的產品開發經驗。Innov Heart的核心產品Saturn用經房間隔的介入方式植入，最大程度避免手術創傷，縮短術後恢復時間，創新性地將瓣環重建技術與瓣膜置換技術相結合，提升器械適配性，適合各種常見的二尖瓣結構。Saturn產品的引進將有望使中國二尖瓣反流患者能夠同步共用全球範圍內最先進的經導管二尖瓣置換術治療方式。
未來，集團將繼續採用"引進落地"及"同步國產化自主研發"的發展路徑，實現本土+全球研發生產的雙體系建設，加速創新產品上市的同時完善自身的研發實力，深入推進全球化平台發展，"十年磨一劍"，將該板塊打造成為中國乃至全球領先的"心腦血管精準介入診療平台"。
集團堅持以患者需求為核心，以科技創新為驅動，採用"全球化運營佈局，雙循環經營發展"策略，針對尚未滿足的臨牀需求，加大對全球創新產品和先進技術的投入，豐富和完善產品管線及產業佈局。集團已在心腦血管精準介入診療、核藥及基因介入治療抗腫瘤以及抗病毒抗感染三個戰略方向形成了"兩彈一星"的創新戰略，致力於打造國際領先的精準介入診療平台，並發展成為國際一流的核藥及基因介入腫瘤診療平台以及重症抗感染領域的科技龍頭企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
